Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix

Gynecologic and Obstetric Investigation

Volumn 56, Issue 1, 2003, Pages 28-34

  Santin, Alessandro D ^a,d,e   Bellone, S ^a,d   Parrish, R S ^b   Coke, C ^b   Dunn, D ^a   Roman, J ^a   Theus, J W ^b   Cannon, M J ^b   Parham, G P ^c   Pecorelli, S ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Blood transfusion; Cervical cancer; Chemoradiation; Local control; Radiotherapy; Survival

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD ANALYSIS; BLOOD AUTOTRANSFUSION; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HYPOTHESIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 0041923626     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072328     Document Type: Article

References (43)

1. Dische S: Radiotherapy and anemia-the clinical experience. Radiother Oncol 1991;20:35-40.
2. Brown JM: The hypoxic cell: A target for selective cancer therapy. 18th Bruce F. Cain Memorial Award lecture. Cancer Res 1999;59:5863-5870.
3. Vigario G, Kurohara SS, George FW: Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Ther Radiol 1973;105:649-652.
4. Thomson JM, Spratt JS: Factors affecting survival in over 500 patients with stage II carcinoma of the cervix. Radiology 1977;123:181-183.
5. Kapp DS, Fisher D, Gutierre E, Kohorn EI, Schwartz PE: Pretreatment prognostic factors in carcinoma of the uterine cervix: A multivariate analysis of the effect of age, histology and blood counts on survival. Int J Radiat Oncol Biol Phys 1983;9:445-455.
6. Girinski T, Pejovic-Lenfant MH, Bourhis J, Campana F, Cosset JM, Petit C, Mlaise EP, Haie C, Gerbaulet A, Chassagne D: Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by RT: Results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989;16:37-42.
7. Bush RS, Jenkin RD, Allt WEC, Beale FA, Bean H, Dembo AJ: Definitive evidence for hypoxic cells influence cure in cancer therapy. Br J Cancer 1978;37:302-306.
8. Poskitt TR: Radiation therapy and the role of red blood cell transfusion. Cancer Invest 1987;5:231-236.
9. Fyles AW, Milosevic M, Pintilie M, Syed A, Hill RP: Anemia, hypoxia and transfusion in patients with cervix cancer: A review. Radiother Oncol 2000;57:13-19.
10. Vigario G, Kurohara SS, George FW III: Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Ther Radiol 1973;106:649-652.
11. Girinsky T, Rey A, Roche B, , Haie C, Gerbaulet A, Randrianarivello H, Chassagne D: Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27:1051-1056.
12. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.
13. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-1690.
14. Opelz G, Sengar DPS, Mickey MR, Terasaki PI: Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973;5:253-259.
15. Graves TA, Cioffi WG, Mason AD, McManus WF, Pruitt BA: Relationship of transfusion and infection in a burn population. J Trauma 1989;29:948-954.
16. Tartter PI: Blood transfusion and postoperative infections. Transfusion 1989;29:456-459.
17. Blumberg N, Heal JM: The transfusion immunomodulation theory: The th1/ th2 paradigm and an analogy with pregnancy as a unifying mechanism. Semin Hematol 1996;33:329-340.
18. Wheatley T, Weitch PS: Effect of blood transfusion on postoperative immunocompetence. Br J Anaesth 1997;78:489-492.
19. Blumberg N, Heal JM: Blood transfusion immunomodulation. The silent epidemic. Arch Pathol Lab Med 1998;122:117-119.
20. Busch ORC, Hop WCJ, Hoynck van Papendrecht MAW, Marquet RL, Jeekel J: Blood transfusion and prognosis in colorectal cancer. N Eng J Med 1993;328:1372-1376.
21. Onsurd M, Thorsby E: Long term changes in natural killer cytotoxicity after external pelvic radiotherapy. Int J Radiat Oncol Biol Phys 1981;7:609-614.
22. Petrini B, Wasserman J, Blomgren H: T cell subsets in patients treated with pelvic irradiation for cancer. J Clin Lab Immunol 1985;17:147-148.
23. Balaram P, Pillai R, Padmanabhan TK, Abraham T, Hareendran NK, Nair MK: Immune function in malignant cervical neoplasia: A multiparameter analysis. Gynecol Oncol 1988;31:409-423.
24. Pillai R, Balaram P, Chidambaram S, Padmanabhan TK, Nair MK: Development of an immunological staging system to prognosticate disease course in malignant cervical neoplasia. Gynecol Oncol 1990;37:200-205.
25. Brittenden J, Heys SD, Ross J, Eremin O: Natural killer cells and cancer. Cancer 1996;77:1226-1243.
26. Brinton LA: Epidemiology of cervical cancer: Overview; in Munoz N, Bosh F, Shah KV, Meheus A (eds): The Epidemiology of Human Papillomavirus and Cervical cancer. Lyon, IARC Science, 1992, vol 119, pp 3-23.
27. Penn I: Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1988;53:539-545.
28. Rellihan MA, Dooley DP, Burke TW, Berkland ME, Longfield RN: Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection. Gynecol Oncol 1990;36:435-438.
29. Morison WL: Viral warts, herpes simplex, and herpes zoster in patients with secondary immune deficiencies and neoplasms. Br J Dermatol 1975;92:625-630.
30. Alexander M, Salgaller ML, Celis E, Sette A, Barnes WA, Rosenberg SA, Steller MA: Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996;175:1586-1593.
31. Evans EM-L, Man S, Evans AS, Borysiewicz LK: Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997;57:2943-2950.
32. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Zhan DJ, Pecorelli S, Parham GP, Cannon MJ: Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7 pulsed autologous dendritic cells in patients with HPV 16 and 18 positive cervical cancer. J Virol 1999;73:5402-5410.
33. Meryman HT: Transfusion-induced alloimmunization and immunosuppression and the effect of leukocyte depletion. Transfus Med Rev 1989;3:180-193.
34. Kaplan J, Sarnaik S, Gitlin J, Lusher J: Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood 1984;64:308-310.
35. Kalechman Y, Gafter U, Sobelman D, Sredini B: The effect of a single whole-blood transfusion on cytokine secretion. J Clin Immunol 1990;10:99-105.
36. Tseng CJ, Pao CC, Lin JD, Soong YK, Hong JH, Hsueh S: Detection of human papillomavirus type 16 and 18 mRNA in peripheral blood of advanced cervical cancer patients and its association with prognosis. J Clin Oncol 1999;17:1391-1396.
37. Blumberg N, Agarwal MM, Chuang C: A possible association between survival time and transfusion in cervical cancer. Yale J Biol Med 1988;61:493-500.
38. Santin AD, Bellone S, Palmieri M, Bossini B, Dunn D, Roman JJ, Pecorelli S, Cannon M, Parham GP: Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: Role of interleukin-10. Int J Radiat Oncol Biol Phys 2002;54:1345-1355.
39. Sardi J, Giaroli A, Sananes C, Rueda NG, Vighi S, Ferreira M, Bastardas M, Paniceres G, di Paola G: Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma cervix uteri: An unexpected therapeutic management. Int J Gynecol Cancer 1996;6:85-93.
40. Sardi J, Giaroli A, Sananes C, Bermudez A, Ferreira MH, Soderini AH, Snaidas L, Guardado N, Anchezar P, Contreras Ortiz O, di Paola G: Neoadjuvant chemotherapy in cervical carcinoma stage IIB: A randomized controlled trial. Int J Gynecol Cancer 1998;8:441-450.
41. Lavey RS, Dempsey H: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:1147-1152.
42. Dusenbery KE, McGuire WA, Holt PJ, Carson LF. Fowler JM, Twiggs LB, Potish RA: Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994;29:1079-1084.
43. Berdel WE, Oberberg D, Reufi B, Thiel E: Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 1991;63:5-8.